1. Wheatley LM, Togias A. Allergic rhinitis. New England Journal of Medicine. 2015;372(5):456-463.
2. Abramson HA. Psychic factors in allergy and their treatment.Annals of Allergy. 1956;14(2):145-151.
3. Czubalski K, Zawisza E. The role of psychic factors in patients with allergic rhinitis. Acta oto-laryngologica. 1976;81(3-6):484-488.
4. del Cuvillo A, Sastre J, Bartra J, et al. Placebo Effect in Clinical Trials Involving Patients with Allergic Rhinitis. Journal of Investigational Allergology Clinical Immunology. 2011;21(3):40-45.
5. Pfaar O, Agache I, Bergmann KC, et al. Placebo effects in allergen immunotherapy—an EAACI Task Force Position Paper. Allergy.2021;76(3):629-647.
6. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nature Reviews Drug Discovery. 2013;12(3):191-205.
7. Schedlowski M, Enck P, Rief W, Bingel U. Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice. Pharmacological reviews.2015;67(3):697-730.
8. Colloca L, Barsky AJ. Placebo and nocebo effects. New England Journal of Medicine. 2020;382(6):554-561.
9. Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome.PloS one. 2010;5(12):e15591.
10. Lembo A, Kelley JM, Nee J, et al. Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial.Pain. 2021.
11. Carvalho C, Caetano JM, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain. 2016;157(12):2766-2772.
12. Kleine-Borgmann J, Schmidt K, Hellmann A, Bingel U. Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: a randomized controlled trial.Pain. 2019;160(12):2891-2897.
13. Carvalho C, Pais M, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo for chronic low back pain: a 5-year follow-up.PAIN. 2021;162(5):1521-1527.
14. Kam-Hansen S, Jakubowski M, Kelley JM, et al. Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks.Science Translational Medicine. 2014;6(218).
15. Hoenemeyer T, Kaptchuk T, Mehta T, Fontaine K. Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial. Scientific Reports. 2018;8(1):2784-2784.
16. Zhou ES, Hall KT, Michaud AL, Blackmon JE, Partridge AH, Recklitis CJ. Open-label placebo reduces fatigue in cancer survivors: a randomized trial. Supportive Care in Cancer. 2019;27(6):2179-2187.
17. Kelley JM, Kaptchuk TJ, Cusin C, Lipkin S, Fava M. Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial. Psychotherapy and Psychosomatics. 2012;81(5):312-314.
18. Nitzan U, Carmeli G, Chalamish Y, et al. Open-Label placebo for the treatment of unipolar depression: Results from a randomized controlled trial. Journal of Affective Disorders. 2020;276:707-710.
19. Schaefer M, Denke C, Harke R, Olk N, Erkovan M, Enge S. Open-label placebos reduce test anxiety and improve self-management skills: A randomized-controlled trial. Scientific Reports. 2019;9(13317).
20. von Wernsdorff M, Loef M, Tuschen-Caffier B, Schmidt S. Effects of open-label placebos in clinical trials: a systematic review and meta-analysis. Scientific Reports. 2021;11(1):1-14.
21. Schaefer M, Harke R, Denke C. Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial. Psychotherapy and Psychosomatics. 2016;85(6):373-374.
22. Schaefer M, Sahin T, Berstecher B. Why do open-label placebos work? A randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis. PLoS ONE. 2018;13(3):e0192758.
23. Kube T, Hofmann VE, Glombiewski JA, Kirsch I. Providing open-label placebos remotely – A randomized controlled trial in allergic rhinitis.PLoS ONE. 2021;16(3):e0248367.
24. Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper.Allergy. 2014;69(7):854-867.
25. Howe LC, Goyer JP, Crum AJ. Harnessing the placebo effect: Exploring the influence of physician characteristics on placebo response.Health Psychology. 2017;36(11):1074.
26. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008;336(7651):999-1003.
27. Locher C, Nascimento AF, Kirsch I, Kossowsky J, Meyer A, Gaab J. Is the rationale more important than deception? A randomized controlled trial of open-label placebo analgesia. Pain.2017;158(12):2320-2328.
28. Kube T, Rief W, Vivell MB, et al. Deceptive and Nondeceptive Placebos to Reduce Pain: An Experimental Study in Healthy Individuals.The Clinical Journal of Pain. 2020;36(2):68-79.
29. Juniper E, Thompson A, Ferrie P, Roberts J. Development and Validation of the Mini Rhinoconjunctivitis Quality of Life Questionnaire. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology.2000;30(1):132-140.
30. Calderón MA, Casale TB, Demoly P. Validation of patient-reported outcomes for clinical trials in allergic rhinitis: a systematic review.The Journal of Allergy and Clinical Immunology: In Practice.2019;7(5):1450-1461. e1456.
31. Tabachnick BG, Fidell LS. Using multivariate statistics. 6th ed. Harlow, England: Pearson; 2014.
32. Enders CK. Using the Expectation Maximization Algorithm to Estimate Coefficient Alpha for Scales with Item-Level Missing Data.Psychological Methods. 2003;8(3):322-337.